eXoZymes Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.00 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $5.83Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $54.2M Enterprise Value $49.8M Shares Outstanding 8.6M diluted Next Earnings Date13 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary eXoZymes Inc. (NASDAQ: EXOZ) is a pioneer in cell-free biomanufacturing, utilizing AI-engineered enzymes (exozymes) to bypass the biological limitations of living cells. While its technology has achieved significant validation—including a successful 100x pilot scale-up of its flagship N-trans-caffeoyltyramine (NCT) compound with Cayman Chemical—the company remains in a pre-revenue development stage. High R&D expenses and public company overhead continue to drive substantial net losses ($2.37 million in Q1 2026). Although the recently closed $5.95 million public offering in June 2026 provides a temporary cash runway, the highly dilutive warrant structure (including a potential reset to $0.001) and going concern warnings warrant a cautious 'Hold' stance until commercial revenues materialize. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Delays in regulatory approvals or scaling hurdles for NCT production. Continued high cash burn forces further highly dilutive equity raises under the $50 million shelf registration, triggering the warrant reset clause to $0.001 and severely diluting existing shareholders. Base CaseCentral scenario The company successfully leverages its $5.95 million capital injection to advance NCT commercialization, secure GRAS certification, and establish long-term contract manufacturing partnerships. R&D expenses remain high but are partially offset by non-dilutive government grants. The stock stabilizes as pilot runs continue to validate the cell-free platform's scalability. Bull CaseUpside scenario Successful commercialization of NCT in the over-the-counter metabolic wellness market by 2027, followed by high-value pharmaceutical licensing partnerships for cannabinoid analogs and other pipeline assets, driving rapid revenue growth and path to profitability. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |